Advertisement
Organisation › Details
Orchard Therapeutics (Group)
Orchard Therapeutics is a fully integrated commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with serious and life-threatening rare diseases through innovative gene therapies. Orchard’s portfolio of autologous ex vivo gene therapies includes Strimvelis®, the first autologous ex vivo gene therapy approved by the European Medicines Agency for adenosine deaminase severe combined immunodeficiency (ADA-SCID). Additional programs for neurometabolic disorders, primary immune deficiencies and hemoglobinopathies include three advanced registrational studies for metachromatic leukodystrophy (MLD), ADA-SCID and Wiskott-Aldrich syndrome (WAS), clinical programs for X-linked chronic granulomatous disease (X-CGD) and transfusion-dependent beta-thalassemia (TDBT), as well as an extensive preclinical pipeline. Orchard currently has offices in the U.K. and the U.S., including London, San Francisco and Boston. *
Start | 2015-09-02 established | |
Industry | gene therapy | |
Industry 2 | DRUGS, ORPHAN | |
Person | Rothera, Mark (Freeline Therapeutics –202202 CEO before Orchard Therapeutics + PTC Tx + Aegerion + Shire RESIGNED 2/22) | |
Person 2 | Thomas, Frank (Orchard Therapeutics 201801– CFO + CBO before AMAG Pharmaceuticals + Molecular Biometrics Inc) | |
Region | London, Greater London | |
Country | United Kingdom (GB) | |
Street | 108 Cannon Street | |
City | EC4N 6EU London | |
Tel | +44-203-384-6700 | |
Address record changed: 2024-01-05 | ||
Basic data | Employees | n. a. |
Currency | USD | |
Annual sales | 2,076,000 (sales, product, consolidated (2018) 2018-12-31) | |
Profit | -230,495,000 (2018-12-31) | |
Cash | 335,844,000 (2018-12-31) | |
* Document for »About Section«: Orchard Therapeutics Ltd.. (1/7/19). "Press Release: Orchard Therapeutics Highlights Recent Accomplishments and 2019 Strategic Priorities as a Global Leader in Gene Therapy". Boston & London. | ||
Record changed: 2023-07-10 |
Advertisement
More documents for Orchard Therapeutics (Group)
- [1] Oxford Biomedica plc. (3/18/20). "Press Release: Building the Group for Future Growth. Business Update". Oxford....
- [2] 4BIO Capital (4BIO Ventures Management Ltd.). (9/9/19). "Press Release: 4BIO Capital Raises $50 million in First Close of New Advanced Therapies Fund". London & Boston, MA....
- [3] Orchard Therapeutics Ltd.. (3/27/19). "Press Release: Orchard Therapeutics Presents New Registrational Data Demonstrating Sustained Clinical Benefit of OTL-200 for the Treatment of MLD". Boston, MA & London....
- [4] Orchard Therapeutics Ltd.. (3/21/19). "Press Release: Orchard Therapeutics Reports 2018 Financial Results and Reviews Recent Business Highlights". Boston, MA & London....
- [5] Orchard Therapeutics Ltd.. (3/18/19). "Press Release: Orchard Therapeutics Strengthens Global Manufacturing and Supply Chain Leadership with Appointment of Ran Zheng as Chief Technical Officer". Boston, MA & London....
- [6] Orchard Therapeutics Ltd.. (3/4/19). "Press Release: Orchard Therapeutics to Present at the Cowen 39th Annual Health Care Conference on March 11, 2019". Boston, MA & London....
- [7] Orchard Therapeutics Ltd.. (2/25/19). "Press Release: Orchard Therapeutics Presents Clinical Proof-of-Concept Data for OTL-102 for the Treatment of X-CGD". Boston, MA & London....
- [8] Orchard Therapeutics Ltd.. (2/22/19). "Press Release: Orchard Therapeutics Presents Two-year Follow-up Data Versus Historical Control from Registrational Trial of OTL-101 for the Treatment of ADA-SCID". Boston, MA & London....
- [9] Orchard Therapeutics Ltd.. (1/7/19). "Press Release: Orchard Therapeutics Highlights Recent Accomplishments and 2019 Strategic Priorities as a Global Leader in Gene Therapy". Boston & London....
- [10] Orchard Therapeutics Ltd.. (1/2/19). "Press Release: Orchard Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference on January 9, 2019". Boston & London....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top